期刊文献+

卡培他滨加奥沙利铂治疗晚期结直肠癌的临床疗效分析 被引量:7

原文传递
导出
摘要 目的探讨卡培他滨加奥沙利铂(xEL0x)治疗晚期结直肠癌的疗效与安全性。方法回顾性分析2002年6月至2008年6月收治的28例具有完整临床资料的晚期结直肠癌患者接受XELOX方案治疗的情况,卡培他滨1000mg/m2,口服,2次/d,第1~14天,奥沙利铂130mg/m2,静脉滴注,2~6h,第1天,21d为1个周期,所有患者均完成至少2个周期化疗。结果28例患者共进行152个周期化疗,中位数4个周期(2。10个周期),部分缓解12例,稳定11例,进展5例,有效率42.9%。中位疾病进展时间6.4个月(2—24个月),中位生存时间10个月(4~33个月),中位随访时间13个月(2~35个月),1年生存率为60.7%(17/28),2年生存率为17.9%(5/28)。主要不良反应是骨髓抑制、神经系统毒性、手足综合征、消化道反应、肝功能异常等,无明显肾毒性和心脏毒性,未发生因化疗产生严重不良反应而终止治疗者,无化疗相关性死亡病例。结论XELOX方案治疗晚期结直肠癌疗效确切,安全可靠,操作简便,值得临床深入研究及推广应用。
出处 《中国医师进修杂志》 2010年第4期50-52,共3页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献8

  • 1徐瑞华,邱妙珍.晚期结直肠癌化疗的研究进展[J].癌症,2008,27(6):661-666. 被引量:51
  • 2Grothey A.A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer.Nat Clin Pract Oncol,2009,6(1):10-11.
  • 3Levey AS,Bosch JP,Lewis JB,et al.A more accurate method to estimate glomerular filtration rate from serum creatinine:a new prediction equation.Modification of Diet in Renal Disease Study Group.Ann Intern Med,1999,130(6):461-467.
  • 4Rivers F,Vega-Villegas ME,López-Brea MF.Chemotherapy of advanced gastric cancer.Cancer Treat Rev,2007,33(4):315-324.
  • 5Feliu J,Salud A,Escudero P,et al.XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.Br J Cancer,2006,94(7):969-975.
  • 6Martoni AA,Pinto C,Di Fabio F,et al.Capecitabine plus oxalipiatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as frost-line treatment in advanced colorectal cancer:a GOAM phase Ⅱ randomised study (FOCA trial).Eur J Cancer,2006,42(18):3161-3168.
  • 7Porschen R,Arkenan HT,Kubicka S,et al.Phase Ⅲ study of capecitabine plus oxaliplatin comparad with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer:a final report of the AIO Colorectal Study Croup.J Clin Oncol,2007,25 (7):4217-4223.
  • 8Díaz-Rubio E,Tabemero J,Gómez-Espana A,et al.Phase Ⅲ study of capecitabine plus oxaliplatin compared with continuousinfusion fluorouraeil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.J Clin Oncol,2007,25 (27):4224-4230.

二级参考文献37

  • 1Cats A. New development in systemic chemotherapy in advanced colorectal cancer [J]. Seand J Gastroenterol Suppl, 2003, (239) : 78-86.
  • 2The Advanced Colorectal Cancer MetaAnalysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate [J]. J Clin Oncol, 1992,10(6) : 896-903.
  • 3Poon M A, O'Connell M J, Wieand H S, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer [J]. J Clin Oncol, 1991,9(11):1967- 1972.
  • 4de Gramont A, Bosset J F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluoronracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study [J]. J Clin Oncol, 1997,15(2): 808-815.
  • 5Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase Ⅱ studies of oxaliplatin (LOHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluorepyrimidines [J]. Ann Oncol, 1996,7( 1 ) :95-98.
  • 6Becouarn Y, Ychou M, Ducreux M, et al. Phase H trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers [J]. J Clin Oncol, 1998,16 ( 8 ) : 2739-2744.
  • 7Giacchetti S, Perpoint B, Zidani R, et al. Phase Ⅲ muhicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J]. J Clin Oncol, 2000,18( 1 ) : 136-147.
  • 8de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J]. J Clin Oncol, 2000,18(16): 2938-2947.
  • 9Conti J A, Kemeny N E, Saltz L B,et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer [J]. J Clin Oncol, 1996, 14(3) :709-715.
  • 10Pitot H C, Wender D B, O'Connell M J, et al. Phase Ⅱ trial of irinotecan in patients with metastatic colorectal carcinoma [J]. J Clin Oncol, 1997, 15(8) :2910-2919.

共引文献50

同被引文献38

引证文献7

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部